U.S. companies have been standing on the cusp of great innovations for far too long, writes economist Michael Mandel, citing stalled revolutions in tissue generation, micromachines and other fields. Mandel looks at some of the most promising breakthroughs of 1998 and how they've stumbled in the intervening years, due to a lack of investment capital and an aversion to risk.

Related Summaries